MetaCap

CalciMedica (CALC) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quantum Biopharma (QNTM) has outperformed CalciMedica (CALC) over the past year, losing 77.6% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-92.34%QNTM-77.60%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
CALC-94.99%QNTM-98.33%
+41%-32%-105%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus QNTM key metrics
MetricCALCQNTM
Share price$1.26$1.29
Market cap$8.69M$8.29M
1-day change+7.69%-9.15%
YTD return-96.18%-82.33%
1-year return-92.34%-77.60%
5-year return—-98.51%
EPS (TTM)$-4.41$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-29.56M—
52-week high$36.00$12.42
52-week low$1.00$1.26
Distance from 52-week high-96.50%-89.61%
Analyst consensusnonenone
Avg. price target upside+3868.25%+851.16%
Average volume80.15K148.83K
Shares outstanding6.90M6.43M
Employees15—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QNTM has outperformed CALC by 14.7 percentage points over the past year.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

CALC vs QNTM FAQ

Which is bigger, CalciMedica or Quantum Biopharma?

CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.29M for Quantum Biopharma (QNTM).

Which stock has performed better over the past year, CALC or QNTM?

QNTM returned -77.60% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are CalciMedica and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons